Evaluating the clinical significance of RBP4, PAI-1, and some trace elements in women with Polycystic Ovary Syndrome

Abstract

To assess and compare clinical, hormonal, and metabolic factors with blood levels of RBP4, PAI-1, and trace elements in women with and without polycystic ovarian syndrome (PCOS). A cross-sectional clinical investigation was undertaken. From December 2020 until January 2022, samples were taken at the Basrah Hospital for Obstetrics and Children's infertility center. Significant changes (p< 0.05) were in HOMA-IR, E2 and Ts. Levels of PAI-1, RBP4, AMH, LH, LH/FSH, PRL and Cu were significantly (p<0.01) increased, and levels of Se, Zn, Mg and E2/T were significantly (p<0.01) decreased, between the patient (1o PCOS and 2o PCOS) and control groups, the QUICKI level did not differ significantly (p>0.05). Compared to the control group, FSH levels were especially (p<0.05) higher in non-obese PCOS patients and lower in obese PCOS patients. Area under the receiver operating characteristics (ROC) curve (AUC) results indicate RBP4 and PAI-1 may be more effective predictors biomarkers for PCOS in expectant women. While trace elements might be considered a protective factor in the emergence of PCOS, metabolic abnormalities and IR in PCOS-affected individuals are associated with the levels of RBP4 and PAI-1, which appear to be a more acceptable diagnostic marker in the early prediction of PCOS. Keywords: Polycystic Ovary Syndrome, RBP4, PAI-1, Trace elements.